Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients with Loss of Mismatch Repair Expression

Edward R Kost, Philip T Valente, Barnard A. Lynch, Naveen K. Krishnegowda, Alexandria M. Hertz, Kevin L Hall, Nicole D. Riddle, Rajeshwar R Tekmal

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives Approximately 3% to 5% of endometrial cancers (EC) are associated with Lynch syndrome (LS). The clinical characteristics and prevalence of LS have not been well studied in the US Hispanic population. Hispanics are the largest and fastest growing ethnic minority group in the United States. We sought to characterize the demographics, tumor characteristics, and prevalence of loss of mismatch repair (MMR) protein expression in a large Hispanic population with EC. Methods From January 1, 2005, to August 1, 2012, 83 women of Hispanic ethnicity diagnosed with EC 50 years and younger were identified. Clinical and pathologic data were abstracted from the electronic medical record. Tumor studies included immunohistochemistry of MLH1, MSH2, MSH6, and PMS2 and methylation of the MLH1 promoter. Results Ninety-five percent of patients were overweight or obese. The mean body mass index was 40.1 kg/m2, 75% had irregular menses, 36% had diabetes, 46% were nulliparous, and 95% had endometrioid histology. Thirteen patients (15.7%) had tumor MMR deficiency due to a presumed germline mutation (9 MSH6, 3 MSH2, and 1 MLH1). The pattern of MMR protein loss was consistent with the expected binding properties of the MMR heterodimer complexes. No significant difference was found in clinical or pathological variables between patients with and without MMR deficient tumors. Conclusions The prevalence of molecular findings consistent with LS was at least as high as other populations of varied geography, race, and ethnicity. We found no reliable factors to include body mass index, family history, synchronous tumors, or pathologic tumor features to serve as triage markers for which ECs should be screened for MMR protein loss. Our findings support a recommendation for universal screening of ECs utilizing 2-antibody testing with MLH1 promoter methylation testing as indicated up to 60 years or older. Our recommendations should be generalizable to other Hispanic populations in the Southern United States.

Original languageEnglish (US)
Pages (from-to)1129-1136
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume26
Issue number6
DOIs
StatePublished - Jul 1 2016

Fingerprint

DNA Mismatch Repair
Endometrial Neoplasms
Hispanic Americans
Hereditary Nonpolyposis Colorectal Neoplasms
Neoplasms
Methylation
Population
Body Mass Index
Minority Groups
Geography
Proteins
Menstruation
Germ-Line Mutation
Electronic Health Records
Triage
Ethnic Groups
Histology
Immunohistochemistry
Demography
Antibodies

Keywords

  • Endometrial cancer
  • Hispanic
  • Lynch syndrome
  • Mismatch repair protein

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients with Loss of Mismatch Repair Expression. / Kost, Edward R; Valente, Philip T; Lynch, Barnard A.; Krishnegowda, Naveen K.; Hertz, Alexandria M.; Hall, Kevin L; Riddle, Nicole D.; Tekmal, Rajeshwar R.

In: International Journal of Gynecological Cancer, Vol. 26, No. 6, 01.07.2016, p. 1129-1136.

Research output: Contribution to journalArticle

Kost, Edward R ; Valente, Philip T ; Lynch, Barnard A. ; Krishnegowda, Naveen K. ; Hertz, Alexandria M. ; Hall, Kevin L ; Riddle, Nicole D. ; Tekmal, Rajeshwar R. / Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients with Loss of Mismatch Repair Expression. In: International Journal of Gynecological Cancer. 2016 ; Vol. 26, No. 6. pp. 1129-1136.
@article{1ded6e11908a49f28f314a392c6d8533,
title = "Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients with Loss of Mismatch Repair Expression",
abstract = "Objectives Approximately 3{\%} to 5{\%} of endometrial cancers (EC) are associated with Lynch syndrome (LS). The clinical characteristics and prevalence of LS have not been well studied in the US Hispanic population. Hispanics are the largest and fastest growing ethnic minority group in the United States. We sought to characterize the demographics, tumor characteristics, and prevalence of loss of mismatch repair (MMR) protein expression in a large Hispanic population with EC. Methods From January 1, 2005, to August 1, 2012, 83 women of Hispanic ethnicity diagnosed with EC 50 years and younger were identified. Clinical and pathologic data were abstracted from the electronic medical record. Tumor studies included immunohistochemistry of MLH1, MSH2, MSH6, and PMS2 and methylation of the MLH1 promoter. Results Ninety-five percent of patients were overweight or obese. The mean body mass index was 40.1 kg/m2, 75{\%} had irregular menses, 36{\%} had diabetes, 46{\%} were nulliparous, and 95{\%} had endometrioid histology. Thirteen patients (15.7{\%}) had tumor MMR deficiency due to a presumed germline mutation (9 MSH6, 3 MSH2, and 1 MLH1). The pattern of MMR protein loss was consistent with the expected binding properties of the MMR heterodimer complexes. No significant difference was found in clinical or pathological variables between patients with and without MMR deficient tumors. Conclusions The prevalence of molecular findings consistent with LS was at least as high as other populations of varied geography, race, and ethnicity. We found no reliable factors to include body mass index, family history, synchronous tumors, or pathologic tumor features to serve as triage markers for which ECs should be screened for MMR protein loss. Our findings support a recommendation for universal screening of ECs utilizing 2-antibody testing with MLH1 promoter methylation testing as indicated up to 60 years or older. Our recommendations should be generalizable to other Hispanic populations in the Southern United States.",
keywords = "Endometrial cancer, Hispanic, Lynch syndrome, Mismatch repair protein",
author = "Kost, {Edward R} and Valente, {Philip T} and Lynch, {Barnard A.} and Krishnegowda, {Naveen K.} and Hertz, {Alexandria M.} and Hall, {Kevin L} and Riddle, {Nicole D.} and Tekmal, {Rajeshwar R}",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/IGC.0000000000000713",
language = "English (US)",
volume = "26",
pages = "1129--1136",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients with Loss of Mismatch Repair Expression

AU - Kost, Edward R

AU - Valente, Philip T

AU - Lynch, Barnard A.

AU - Krishnegowda, Naveen K.

AU - Hertz, Alexandria M.

AU - Hall, Kevin L

AU - Riddle, Nicole D.

AU - Tekmal, Rajeshwar R

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objectives Approximately 3% to 5% of endometrial cancers (EC) are associated with Lynch syndrome (LS). The clinical characteristics and prevalence of LS have not been well studied in the US Hispanic population. Hispanics are the largest and fastest growing ethnic minority group in the United States. We sought to characterize the demographics, tumor characteristics, and prevalence of loss of mismatch repair (MMR) protein expression in a large Hispanic population with EC. Methods From January 1, 2005, to August 1, 2012, 83 women of Hispanic ethnicity diagnosed with EC 50 years and younger were identified. Clinical and pathologic data were abstracted from the electronic medical record. Tumor studies included immunohistochemistry of MLH1, MSH2, MSH6, and PMS2 and methylation of the MLH1 promoter. Results Ninety-five percent of patients were overweight or obese. The mean body mass index was 40.1 kg/m2, 75% had irregular menses, 36% had diabetes, 46% were nulliparous, and 95% had endometrioid histology. Thirteen patients (15.7%) had tumor MMR deficiency due to a presumed germline mutation (9 MSH6, 3 MSH2, and 1 MLH1). The pattern of MMR protein loss was consistent with the expected binding properties of the MMR heterodimer complexes. No significant difference was found in clinical or pathological variables between patients with and without MMR deficient tumors. Conclusions The prevalence of molecular findings consistent with LS was at least as high as other populations of varied geography, race, and ethnicity. We found no reliable factors to include body mass index, family history, synchronous tumors, or pathologic tumor features to serve as triage markers for which ECs should be screened for MMR protein loss. Our findings support a recommendation for universal screening of ECs utilizing 2-antibody testing with MLH1 promoter methylation testing as indicated up to 60 years or older. Our recommendations should be generalizable to other Hispanic populations in the Southern United States.

AB - Objectives Approximately 3% to 5% of endometrial cancers (EC) are associated with Lynch syndrome (LS). The clinical characteristics and prevalence of LS have not been well studied in the US Hispanic population. Hispanics are the largest and fastest growing ethnic minority group in the United States. We sought to characterize the demographics, tumor characteristics, and prevalence of loss of mismatch repair (MMR) protein expression in a large Hispanic population with EC. Methods From January 1, 2005, to August 1, 2012, 83 women of Hispanic ethnicity diagnosed with EC 50 years and younger were identified. Clinical and pathologic data were abstracted from the electronic medical record. Tumor studies included immunohistochemistry of MLH1, MSH2, MSH6, and PMS2 and methylation of the MLH1 promoter. Results Ninety-five percent of patients were overweight or obese. The mean body mass index was 40.1 kg/m2, 75% had irregular menses, 36% had diabetes, 46% were nulliparous, and 95% had endometrioid histology. Thirteen patients (15.7%) had tumor MMR deficiency due to a presumed germline mutation (9 MSH6, 3 MSH2, and 1 MLH1). The pattern of MMR protein loss was consistent with the expected binding properties of the MMR heterodimer complexes. No significant difference was found in clinical or pathological variables between patients with and without MMR deficient tumors. Conclusions The prevalence of molecular findings consistent with LS was at least as high as other populations of varied geography, race, and ethnicity. We found no reliable factors to include body mass index, family history, synchronous tumors, or pathologic tumor features to serve as triage markers for which ECs should be screened for MMR protein loss. Our findings support a recommendation for universal screening of ECs utilizing 2-antibody testing with MLH1 promoter methylation testing as indicated up to 60 years or older. Our recommendations should be generalizable to other Hispanic populations in the Southern United States.

KW - Endometrial cancer

KW - Hispanic

KW - Lynch syndrome

KW - Mismatch repair protein

UR - http://www.scopus.com/inward/record.url?scp=84977529418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977529418&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000713

DO - 10.1097/IGC.0000000000000713

M3 - Article

C2 - 27327152

AN - SCOPUS:84977529418

VL - 26

SP - 1129

EP - 1136

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -